Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study.
Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, Pérez-Iglesias R, Amado-Señaris JA, Teresa Garcia-Unzueta M, Labad J, Correll C, Ayesa-Arriola R. Crespo-Facorro B, et al. Among authors: valdizan em. Schizophr Res. 2017 Nov;189:134-141. doi: 10.1016/j.schres.2017.01.046. Epub 2017 Feb 20. Schizophr Res. 2017. PMID: 28223031 Clinical Trial.
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.
Crespo-Facorro B, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Ortiz V, Pelayo-Terán JM, Valdizan E, Vazquez-Barquero JL. Crespo-Facorro B, et al. Psychopharmacology (Berl). 2012 Jan;219(1):225-33. doi: 10.1007/s00213-011-2392-3. Epub 2011 Jul 7. Psychopharmacology (Berl). 2012. PMID: 21735072 Clinical Trial.
Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Crespo-Facorro B, Pérez-Iglesias R, Mata I, Ortiz-Garcia de la Foz V, Martínez-Garcia O, Valdizan EM, Vazquez-Barquero JL. Crespo-Facorro B, et al. Among authors: valdizan em. J Clin Psychopharmacol. 2013 Apr;33(2):215-20. doi: 10.1097/JCP.0b013e3182825c1e. J Clin Psychopharmacol. 2013. PMID: 23422371 Clinical Trial.
Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Crespo-Facorro B, Ortiz-García de la Foz V, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Vázquez-Barquero JL, Pérez-Iglesias R. Crespo-Facorro B, et al. Among authors: valdizan em. Schizophr Res. 2013 Jul;147(2-3):375-82. doi: 10.1016/j.schres.2013.04.014. Epub 2013 May 1. Schizophr Res. 2013. PMID: 23643328 Clinical Trial.
Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.
Crespo-Facorro B, de la Foz VO, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Martinez-Garcia O, Pérez-Iglesias R. Crespo-Facorro B, et al. Among authors: valdizan em. Psychopharmacology (Berl). 2014 Jan;231(2):357-66. doi: 10.1007/s00213-013-3241-3. Psychopharmacology (Berl). 2014. PMID: 23958945 Clinical Trial.
Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics.
Ruso-Julve F, Pombero A, Pilar-Cuéllar F, García-Díaz N, Garcia-Lopez R, Juncal-Ruiz M, Castro E, Díaz Á, Vazquez-Bourgón J, García-Blanco A, Garro-Martinez E, Pisonero H, Estirado A, Ayesa-Arriola R, López-Giménez J, Mayor F Jr, Valdizán E, Meana J, Gonzalez-Maeso J, Martínez S, Vaqué JP, Crespo-Facorro B. Ruso-Julve F, et al. Transl Psychiatry. 2019 Nov 18;9(1):306. doi: 10.1038/s41398-019-0647-7. Transl Psychiatry. 2019. PMID: 31740729 Free PMC article.
54 results